What happened with CGEM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cullinan Therapeutics is a drug developer, not yet a seller of approved medicines. It is testing candidates including CLN-978 for autoimmune diseases and CLN-049 for acute myeloid leukemia and myelodysplastic syndromes. It has no products approved for commercial sale and has not generated product-sales revenue. It has primarily funded its work by selling shares and licensing or selling rights to drug candidates.
Its clearest prospective route to income is zipalertinib, a lung-cancer drug developed with Taiho. The partners share development costs for the agreed indication, and Taiho will handle commercialization. Cullinan is entitled to a share of future pre-tax profits from potential U.S. sales and regulatory milestone payments from Taiho. It plans to use potential zipalertinib proceeds to support CLN-978 and CLN-049 development. This income path depends on Taiho and on successful development, regulatory approval and commercialization; no candidate can be sold before marketing approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cullinan's prospects depend on autoimmune and AML trial results and on Taiho advancing and commercializing zipalertinib, whose potential U.S. pre-tax profits the two companies split equally.
Xencor, Inc. competes with Cullinan in autoimmune antibodies that bring T cells to B cells marked by CD19 or CD20. Xencor earns payments from partners licensing its drug candidates; its autoimmune antibody trials offer a comparison for Cullinan's CLN-978.
ArriVent BioPharma, Inc.'s firmonertinib competes with Cullinan and Taiho's zipalertinib for patients with EGFR exon 20 insertion non-small cell lung cancer. ArriVent had no approved products or revenue in 2025; firmonertinib's development matters to the potential U.S. profits Cullinan would share from zipalertinib.
Oric Pharmaceuticals, Inc.'s enozertinib targets an EGFR-mutant non-small cell lung cancer population that overlaps with Cullinan's zipalertinib. Oric's candidates were not approved for marketing as of year-end 2025, so enozertinib's clinical progress—not product sales—is the comparison to watch.
Climb Bio, Inc.'s budoprutug competes with Cullinan's CLN-978 to treat autoimmune diseases by targeting CD19, but uses a different antibody approach. Climb had no revenue through 2025; budoprutug's development provides a test of the alternatives to Cullinan's T-cell-engaging antibody.
Cabaletta Bio, Inc. develops engineered T-cell treatments that compete with Cullinan's antibodies that recruit T cells against B cells in autoimmune diseases. Cabaletta has not generated product-sales revenue, so its clinical development offers a comparison between cell treatment and Cullinan's proposed ready-to-use CLN-978.
Kyverna Therapeutics, Inc.'s engineered T-cell treatments compete with Cullinan's B-cell-directed antibodies as ways to reset the immune system in autoimmune disease. Watch KYV-102's manufacturing progress: Kyverna intends its whole-blood process to shorten production and avoid apheresis, a potential contrast with Cullinan's proposed ready-to-use CLN-978.
Zenas BioPharma, Inc. competes with Cullinan's CLN-978 by developing CD19-directed treatments for autoimmune diseases. Zenas also receives payments for licensing drug rights to partners; its CD19 programs are the relevant comparison for CLN-978, rather than licensing receipts.
Johnson & Johnson's approved treatment for EGFR exon 20 insertion non-small cell lung cancer sets a benchmark for Cullinan and Taiho's zipalertinib. Johnson & Johnson sells prescription medicines to wholesalers and healthcare organizations; its amivantamab-plus-chemotherapy approval is for first-line treatment, while zipalertinib's cited Phase 2b result was in second-or-later-line patients.
BlossomHill Therapeutics, Inc.'s BH-30643 and Cullinan's zipalertinib pursue overlapping non-small cell lung cancer populations with uncommon EGFR mutations, including exon 20 insertions. BlossomHill develops small-molecule cancer drugs rather than selling commercial products; BH-30643's progress in those patients is the relevant comparison.
Amgen competes with Cullinan's autoimmune pipeline both through antibodies that recruit T cells to CD19-marked cells and through its marketed B-cell-depleting drug UPLIZNA. Amgen earns medicine-sales revenue, largely through U.S. wholesalers; UPLIZNA provides an already-approved comparison for Cullinan's experimental treatments.
Century Therapeutics, Inc.'s CNTY-101 and CNTY-308 cell therapies compete with Cullinan's T-cell-engaging antibodies for B-cell-mediated autoimmune diseases. Century develops donor-derived, stem-cell-based treatments; CNTY-101's CARAMEL trial is the clinical comparison to watch.
Artiva Biotherapeutics, Inc.'s AlloNK offers an alternative cell-based approach to autoimmune treatment that competes with Cullinan's T-cell-engaging antibodies. Artiva had no product-sales revenue through 2025; AlloNK's clinical and manufacturing progress is the comparison for Cullinan's proposed ready-to-use CLN-978.
Black Diamond Therapeutics, Inc. and Cullinan develop drugs that block EGFR in genetically defined non-small cell lung cancer, with overlapping competition in uncommon EGFR mutations. Black Diamond's silevertinib Phase 2 lung-cancer trial is the relevant development to compare with Cullinan's zipalertinib.
Senti Biosciences Holdings, Inc.'s FLT3-targeted cell therapies compete with Cullinan's CLN-049 for acute myeloid leukemia patients. Senti develops gene-circuit-based therapies, while CLN-049 recruits T cells and binds FLT3 regardless of mutation status; progress in Senti's FLT3 programs provides a comparison for that approach.
Molecular Partners AG develops treatments that engage immune cells against acute myeloid leukemia, competing with Cullinan's CLN-049. Molecular Partners earns revenue from research and licensing partners, not commercial product sales; its AML development is more relevant to CLN-049 than changes in milestone-driven revenue.
Aptevo Therapeutics Inc develops immune-engaging treatments for acute myeloid leukemia that compete with Cullinan's CLN-049 for patients. Aptevo's business centers on experimental cancer immunotherapies; its AML program progress is the relevant comparison for Cullinan.
Molecular Partners AG earningsMOLN
Molecular Partners' report can show how another immune-cell-engaging AML treatment is progressing against the same patient market as Cullinan's CLN-049.
Look for Molecular Partners' AML trial progress and any patient data it reports, then compare them with the development stage and disclosed results for Cullinan's CLN-049; the two drugs are not being compared in a head-to-head trial. Strong progress would show that competition for AML patients is advancing and that CLN-049 must establish its own clinical evidence. Limited progress would mean less evidence of a pressing competitor, not proof that CLN-049 works.
Amgen Inc earningsAMGN
Amgen's report, if it breaks out UPLIZNA sales, can show demand for an approved B-cell-depleting treatment in autoimmune disease, a market reference for Cullinan's experimental therapies.
If Amgen reports UPLIZNA sales separately, read them apart from the company's overall sales. Growth would show demand for an existing treatment, so Cullinan would still need to show that a future therapy such as CLN-978 offers added value. Weak sales would mean less evidence of demand for this approved option, not that patients will switch to Cullinan's drugs. Without a separate sales figure, the report cannot settle this question.
Xencor, Inc. earningsXNCR
Xencor's report can show whether its autoimmune antibody trials are advancing an approach that also brings T cells to B cells, a close clinical comparison for Cullinan's CLN-978.
Compare any autoimmune trial progress and patient data Xencor reports with the stage and data of Cullinan's CLN-978 trials. Both target B cells, but they are not being tested against each other in a head-to-head trial. Strong progress would show that a similar approach is advancing and that CLN-978 must establish its value with its own data. Stalled progress or limited data would mean less evidence of a close rival, not proof that CLN-978 works.
Cullinan Therapeutics, Inc. earningsThis company
Cullinan Therapeutics has no product-sales revenue, so this report will show how much it is spending to advance its clinical programs and whether cash use remains consistent with its stated funding runway into 2029.
Read research and development expense alongside cash used in operating activities, then compare both with cash, cash equivalents and investments. Rising expense with faster cash use means advancing programs is consuming more funding; if available resources are shrinking faster, the stated runway into 2029 needs closer scrutiny. Steadier expense without a matching acceleration in cash use means this period has not obviously reduced that cushion, but quarterly spending alone does not prove clinical progress.
ArriVent BioPharma, Inc. earningsAVBP
ArriVent BioPharma's report can show how far firmonertinib has progressed in the same EGFR exon 20 insertion lung-cancer population targeted by Cullinan and Taiho's zipalertinib.
Compare ArriVent's disclosed firmonertinib trial progress and patient data with the trial and regulatory progress of zipalertinib; the drugs are not in a head-to-head trial. Strong progress would show a rival advancing for the same patients, which could affect future treatment choices and the market available to zipalertinib. Cullinan and Taiho are each entitled to 50% of potential U.S. pre-tax profits, so this competition matters to that possible income stream. Limited progress would mean less evidence of competitive pressure, not proof that zipalertinib will be approved or succeed.
